(Q50871306)

24 March 2018

title

Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients. (English)

1 reference

24 March 2018

author

Renaud Du Pasquier

7

1 reference

24 March 2018

Giuseppe Pantaleo

5

object named as

Giuseppe Pantaleo

1 reference

24 March 2018

author name string

Samantha Jilek

1

1 reference

24 March 2018

Amandine Mathias

2

1 reference

24 March 2018

Mathieu Canales

3

1 reference

24 March 2018

Andreas Lysandropoulos

4

1 reference

24 March 2018

Myriam Schluep

6

1 reference

24 March 2018

publication date

20 November 2013

1 reference

24 March 2018

Multiple Sclerosis Journal

published in

1 reference

24 March 2018

volume

20

1 reference

24 March 2018

issue

7

1 reference

24 March 2018

page(s)

837-842

1 reference

24 March 2018

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

The cellular context of T cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Skewed maturation of memory HIV-specific CD8 T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

21 January 2018

CXCR3 in T cell function

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

CCR6 as a mediator of immunity in the lung and gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Effector and suppressor roles for LFA-1 during the development of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

Natalizumab effects on immune cell responses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513208

21 January 2018

Identifiers

DOI

10.1177/1352458513513208

1 reference

24 March 2018

1 reference

24 March 2018